Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MMP13 | P45452 | 8/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.56 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255550 | 0.93 | MAPT (0.61) | MAPTMMP13PPARGROCK2SMN1; SMN2 | |
| SCHEMBL6736771 | 0.93 | MAPT (0.61) | MAPTMMP13PPARGROCK2SMN1; SMN2 | |
| SCHEMBL6255332 | 0.92 | MMP13 (0.63) | MAPTMMP13PPARGROCK2SMN1; SMN2 | |
| SCHEMBL7014327 | 0.91 | MAPT (0.58) | MAPTMMP13PPARGROCK2PTGER4 | |
| SCHEMBL6259580 | 0.91 | MMP13 (0.61) | MAPTMMP13PPARGSLC22A8PTGER4 | |
| SCHEMBL6246256 | 0.89 | MAPT (0.58) | MAPTMMP13PPARGSLC22A8SMN1; SMN2 | |
| SCHEMBL7095851 | 0.89 | MMP13 (0.65) | MAPTMMP13PPARGSLC22A8SMN1; SMN2 | |
| SCHEMBL6258761 | 0.89 | MAPT (0.58) | MAPTMMP13PPARGROCK2SMN1; SMN2 | |
| SCHEMBL7625585 | 0.89 | MMP13 (0.53) | MAPTMMP13PPARGSLC22A8PTGER4 | |
| SCHEMBL6468114 | 0.88 | MMP13 (0.67) | MAPTMMP13ROCK2SLC22A8PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| EP-1530467-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004006912-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | MAPT 4823/4885MMP13 1/4885PPARG 3301/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MAPT 1345/4885MMP13 1/4885PPARG 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.